Psoriatic Arthritis

TOPLINE:

An early serum cortisol concentration of > 237 nmol/L (> 8.6 μg/dL) has been validated as a safe and useful screening test with 100% specificity for predicting recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients on tapering regimes from long‐term chronic glucocorticoid therapy (CGT).

METHODOLOGY:

• A retrospective review of 250-µg Synacthen test (SST) results performed in patients on tapering CGT doses from a single-center rheumatology department over 12 months.
• A total of 60 SSTs were performed in 58 patients, all in the morning (7-12 AM) after withholding CGT for 48 hours.
• Peripheral blood was sampled for cortisol at baseline, 30 minutes, and 60 minutes.
• Adrenal insufficiency (AI) was defined as a peak serum cortisol concentration.

TAKEAWAY:

• The mean duration of CGT (all prednisolone) was 63 months, prescribed primarily for giant cell arteritis/polymyalgia rheumatica (48%) and inflammatory arthritis (18%), with a mean daily dose of 3.4 mg at the time of SST.
• With the investigators’ previously reported basal serum cortisol concentration of > 237 nmol/L (> 8.6 μg/dL) used to confirm an intact HPA axis, no patient with AI would have been missed, but 37 of 51 (73%) unnecessary SSTs in euadrenal patients would have been avoided.
• A basal serum cortisol concentration of > 227 nmol/L had a specificity of 100% for predicting passing the SST, while a basal serum cortisol concentration of ≤ 55 nmol/L had a 100% sensitivity for predicting failure.
• A mean daily prednisolone dosing at the time of SST in patients with AI was significantly higher than that with normal SSTs (5.7 vs 2.9 mg, respectively; P = .01).

IN PRACTICE:

“This offers a more rapid, convenient, and cost‐effective screening method for patients requiring biochemical assessment of the HPA axis with the potential for significant resource savings without any adverse impact on patient safety,” the authors wrote.

SOURCE:

The study was conducted by Ella Sharma, of the Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK, and colleagues and published online on May 19, 2024, as a letter in Clinical Endocrinology.

LIMITATIONS:

Not provided.

DISCLOSURES: 

Not provided.
 

A version of this article appeared on Medscape.com.

TOPLINE:

An early serum cortisol concentration of > 237 nmol/L (> 8.6 μg/dL) has been validated as a safe and useful screening test with 100% specificity for predicting recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients on tapering regimes from long‐term chronic glucocorticoid therapy (CGT).

METHODOLOGY:

• A retrospective review of 250-µg Synacthen test (SST) results performed in patients on tapering CGT doses from a single-center rheumatology department over 12 months.
• A total of 60 SSTs were performed in 58 patients, all in the morning (7-12 AM) after withholding CGT for 48 hours.
• Peripheral blood was sampled for cortisol at baseline, 30 minutes, and 60 minutes.
• Adrenal insufficiency (AI) was defined as a peak serum cortisol concentration.

TAKEAWAY:

• The mean duration of CGT (all prednisolone) was 63 months, prescribed primarily for giant cell arteritis/polymyalgia rheumatica (48%) and inflammatory arthritis (18%), with a mean daily dose of 3.4 mg at the time of SST.
• With the investigators’ previously reported basal serum cortisol concentration of > 237 nmol/L (> 8.6 μg/dL) used to confirm an intact HPA axis, no patient with AI would have been missed, but 37 of 51 (73%) unnecessary SSTs in euadrenal patients would have been avoided.
• A basal serum cortisol concentration of > 227 nmol/L had a specificity of 100% for predicting passing the SST, while a basal serum cortisol concentration of ≤ 55 nmol/L had a 100% sensitivity for predicting failure.
• A mean daily prednisolone dosing at the time of SST in patients with AI was significantly higher than that with normal SSTs (5.7 vs 2.9 mg, respectively; P = .01).

IN PRACTICE:

“This offers a more rapid, convenient, and cost‐effective screening method for patients requiring biochemical assessment of the HPA axis with the potential for significant resource savings without any adverse impact on patient safety,” the authors wrote.

SOURCE:

The study was conducted by Ella Sharma, of the Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK, and colleagues and published online on May 19, 2024, as a letter in Clinical Endocrinology.

LIMITATIONS:

Not provided.

DISCLOSURES: 

Not provided.
 

A version of this article appeared on Medscape.com.

TOPLINE:

An early serum cortisol concentration of > 237 nmol/L (> 8.6 μg/dL) has been validated as a safe and useful screening test with 100% specificity for predicting recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients on tapering regimes from long‐term chronic glucocorticoid therapy (CGT).

METHODOLOGY:

• A retrospective review of 250-µg Synacthen test (SST) results performed in patients on tapering CGT doses from a single-center rheumatology department over 12 months.
• A total of 60 SSTs were performed in 58 patients, all in the morning (7-12 AM) after withholding CGT for 48 hours.
• Peripheral blood was sampled for cortisol at baseline, 30 minutes, and 60 minutes.
• Adrenal insufficiency (AI) was defined as a peak serum cortisol concentration.

TAKEAWAY:

• The mean duration of CGT (all prednisolone) was 63 months, prescribed primarily for giant cell arteritis/polymyalgia rheumatica (48%) and inflammatory arthritis (18%), with a mean daily dose of 3.4 mg at the time of SST.
• With the investigators’ previously reported basal serum cortisol concentration of > 237 nmol/L (> 8.6 μg/dL) used to confirm an intact HPA axis, no patient with AI would have been missed, but 37 of 51 (73%) unnecessary SSTs in euadrenal patients would have been avoided.
• A basal serum cortisol concentration of > 227 nmol/L had a specificity of 100% for predicting passing the SST, while a basal serum cortisol concentration of ≤ 55 nmol/L had a 100% sensitivity for predicting failure.
• A mean daily prednisolone dosing at the time of SST in patients with AI was significantly higher than that with normal SSTs (5.7 vs 2.9 mg, respectively; P = .01).

IN PRACTICE:

“This offers a more rapid, convenient, and cost‐effective screening method for patients requiring biochemical assessment of the HPA axis with the potential for significant resource savings without any adverse impact on patient safety,” the authors wrote.

SOURCE:

The study was conducted by Ella Sharma, of the Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK, and colleagues and published online on May 19, 2024, as a letter in Clinical Endocrinology.

LIMITATIONS:

Not provided.

DISCLOSURES: 

Not provided.
 

A version of this article appeared on Medscape.com.

Supporters of home phototherapy for patients with plaque and guttate psoriasis had plenty to cheer about at the annual meeting of the American Academy of Dermatology (AAD) in March. There, Joel M. Gelfand, MD, professor of dermatology and epidemiology at the University of Pennsylvania in Philadelphia, presented results from the LITE study, a trial that tested the hypothesis that narrowband ultraviolet B phototherapy of psoriasis at home is noninferior to office treatment, based on outcomes that matter to patients, clinicians, and payers. While smaller studies have drawn similar conclusions, LITE was the largest trial of its kind to show what many dermatologists have suspected for years: Home phototherapy can be an effective first-line treatment for patients with moderate to severe psoriasis.

The co-primary outcomes in the LITE study were a Physician’s Global Assessment (PGA) score of 0/1 (clear, almost clear) and a Dermatology Life Quality Index (DLQI) score of 5 or less (small, no effect on health-related quality of life).

Dr. Gelfand and colleagues at 42 sites in the United States enrolled 783 patients aged 12 years and older who had plaque or guttate psoriasis and were candidates for phototherapy at home or in an office setting. Following 12 weeks of treatment, 25.6% of patients in the office-based phototherapy group achieved a PGA score of 0/1 compared with 32.8% of patients in the home-based phototherapy group (P > .0001 for noninferiority, non-response imputation for missing data). Similarly, 33.6% of patients in the office-based phototherapy group achieved a DLQI score of 5 or less compared with 52.4% of patients in the home-based phototherapy group (P > .0001 for noninferiority, non-response imputation for missing data).

Courtesy Dr. Gelfand

A Safe and Effective Option

“I think that it’s important for physicians, insurance companies, and patients with psoriasis to understand that this is a very safe and effective form of therapy,” Craig A. Elmets, MD, professor of dermatology at The University of Alabama at Birmingham, said in an interview. “For people who are not interested in systemic medications or who have contraindications to systemic medications, phototherapy would be ideal,” added Dr. Elmets, first author of the joint AAD–National Psoriasis Foundation (NPF) guidelines for the management and treatment of psoriasis with phototherapy, published in 2019.

Factors beyond efficacy support the role of home phototherapy, Dr. Gelfand said, including the fact that it costs 10-100 times less than biologics for psoriasis and that office-based phototherapy is not available in 90% of counties in the United States. However, insurance coverage of home phototherapy “is highly variable because until the LITE study, there was no large-scale US data to support its use,” he told this news organization.

“Also, insurance companies are broken up into two parts: Durable medical goods and the medical side such as pharmacy costs, and they are siloed. The durable medical goods side views phototherapy as expensive, while the pharmacy side views it as dirt cheap. This is part of the problem with our health system. A lot of things are siloed and don’t make any sense,” said Dr. Gelfand, director of the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania. By working with the NPF and payers, he added, “we’re hoping ... to transform the way insurance companies think about covering home phototherapy.”

In the meantime, he and Dr. Elmets shared practical ways to optimize access to home phototherapy for psoriasis patients:

Have the discussion. Patients “rarely bring this up as an option,” Dr. Elmets said, so the onus is on clinicians to talk about it. In his view, the ideal candidate “is averse to using systemic agents but whose disease is beyond the point where topical medicines alone will work. One of the advantages of phototherapy is that it doesn’t have immunosuppressive effects.”

Clinicians and patients can learn about the efficacy and safety of phototherapy for psoriasis, including home-based options, on the NPF’s web site and by reading the 2019 joint AAD-NPF guidelines.

Shared decision-making is key. “When a patient comes in, I’ll discuss what their treatment options are and [we] will decide upon a course of action based on their unique needs and preferences [and] if it’s medically appropriate, meaning they have the type of psoriasis likely to respond to phototherapy,” Dr. Gelfand said. A patient with psoriasis mainly on the fingernails or genitals “is not a good candidate for phototherapy. If it’s on the trunk or extremities, that patient would be a good candidate.”

Home phototherapy candidates also must be willing and able to operate a machine and have dedicated space in their dwelling for it (most units are about the size of a door). Patients also have to be reliable, follow directions, and come back in person for follow-up appointments “so we can assess their response to treatment and fine-tune things as necessary and make sure they’re not developing any skin damage,” Dr. Gelfand said.

Educate yourself about existing options. Home phototherapy units from manufacturers such as Daavlin, National Biological Corporation, and SolRx range between $1200 and $6000 in cost, Dr. Gelfand said. He and his colleagues used the Daavlin 7 series in the LITE study. That unit features an integrated dosimetry system that delivers the correct dose of energy based on parameters that the prescribing clinician recommends. Settings are based on the patient’s skin type and how much the prescriber wants to increase the dose for each treatment. “The machine does the rest,” he said. “It knows what dose to give, so they get the same dosing as they would in an office situation.”

Smaller home-based phototherapy units designed to treat the hands and feet are available. So are handheld units to treat the scalp. “These can be a nice option for patients who have a few spots, but if the disease is moderate to severe, then it’s going to be pretty laborious to [use them],” Dr. Elmets said.

Remember that phototherapy is not a cure-all. According to the joint AAD-NPF guidelines, most phototherapy regimens require treatments two to three times per week for 10-14 weeks. Once patients achieve their home phototherapy treatment goal, Dr. Elmets often recommends treatments one to two times per week for maintenance.

“Patients with psoriasis have a lifetime condition,” he noted. “There are certainly cases where people have gone on phototherapy, cleared, and then stopped for a period of time. If they flare up, they can always go back to phototherapy. Usually, people who are on phototherapy use some type of topical agents to touch up areas that are resistant.”

Expect pushback from insurers on coverage. While Medicare and some integrated health plans cover home phototherapy, expect to spend time writing letters or placing phone calls to insurance companies to convince them why they should cover home phototherapy for candidate psoriasis patients. “Usually there’s a lot of letter writing and a long delay in getting approval,” Dr. Elmets said.

Dr. Elmets and Dr. Gelfand reported no relevant financial relationships. The LITE study was funded by the Patient-Centered Outcomes Research Institute. Research partners included the National Psoriasis Foundation and Daavlin, which provided the home phototherapy machines and covered the cost of shipping the devices.

A version of this article appeared on Medscape.com.

Supporters of home phototherapy for patients with plaque and guttate psoriasis had plenty to cheer about at the annual meeting of the American Academy of Dermatology (AAD) in March. There, Joel M. Gelfand, MD, professor of dermatology and epidemiology at the University of Pennsylvania in Philadelphia, presented results from the LITE study, a trial that tested the hypothesis that narrowband ultraviolet B phototherapy of psoriasis at home is noninferior to office treatment, based on outcomes that matter to patients, clinicians, and payers. While smaller studies have drawn similar conclusions, LITE was the largest trial of its kind to show what many dermatologists have suspected for years: Home phototherapy can be an effective first-line treatment for patients with moderate to severe psoriasis.

The co-primary outcomes in the LITE study were a Physician’s Global Assessment (PGA) score of 0/1 (clear, almost clear) and a Dermatology Life Quality Index (DLQI) score of 5 or less (small, no effect on health-related quality of life).

Dr. Gelfand and colleagues at 42 sites in the United States enrolled 783 patients aged 12 years and older who had plaque or guttate psoriasis and were candidates for phototherapy at home or in an office setting. Following 12 weeks of treatment, 25.6% of patients in the office-based phototherapy group achieved a PGA score of 0/1 compared with 32.8% of patients in the home-based phototherapy group (P > .0001 for noninferiority, non-response imputation for missing data). Similarly, 33.6% of patients in the office-based phototherapy group achieved a DLQI score of 5 or less compared with 52.4% of patients in the home-based phototherapy group (P > .0001 for noninferiority, non-response imputation for missing data).

Courtesy Dr. Gelfand

A Safe and Effective Option

“I think that it’s important for physicians, insurance companies, and patients with psoriasis to understand that this is a very safe and effective form of therapy,” Craig A. Elmets, MD, professor of dermatology at The University of Alabama at Birmingham, said in an interview. “For people who are not interested in systemic medications or who have contraindications to systemic medications, phototherapy would be ideal,” added Dr. Elmets, first author of the joint AAD–National Psoriasis Foundation (NPF) guidelines for the management and treatment of psoriasis with phototherapy, published in 2019.

Factors beyond efficacy support the role of home phototherapy, Dr. Gelfand said, including the fact that it costs 10-100 times less than biologics for psoriasis and that office-based phototherapy is not available in 90% of counties in the United States. However, insurance coverage of home phototherapy “is highly variable because until the LITE study, there was no large-scale US data to support its use,” he told this news organization.

“Also, insurance companies are broken up into two parts: Durable medical goods and the medical side such as pharmacy costs, and they are siloed. The durable medical goods side views phototherapy as expensive, while the pharmacy side views it as dirt cheap. This is part of the problem with our health system. A lot of things are siloed and don’t make any sense,” said Dr. Gelfand, director of the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania. By working with the NPF and payers, he added, “we’re hoping ... to transform the way insurance companies think about covering home phototherapy.”

In the meantime, he and Dr. Elmets shared practical ways to optimize access to home phototherapy for psoriasis patients:

Have the discussion. Patients “rarely bring this up as an option,” Dr. Elmets said, so the onus is on clinicians to talk about it. In his view, the ideal candidate “is averse to using systemic agents but whose disease is beyond the point where topical medicines alone will work. One of the advantages of phototherapy is that it doesn’t have immunosuppressive effects.”

Clinicians and patients can learn about the efficacy and safety of phototherapy for psoriasis, including home-based options, on the NPF’s web site and by reading the 2019 joint AAD-NPF guidelines.

Shared decision-making is key. “When a patient comes in, I’ll discuss what their treatment options are and [we] will decide upon a course of action based on their unique needs and preferences [and] if it’s medically appropriate, meaning they have the type of psoriasis likely to respond to phototherapy,” Dr. Gelfand said. A patient with psoriasis mainly on the fingernails or genitals “is not a good candidate for phototherapy. If it’s on the trunk or extremities, that patient would be a good candidate.”

Home phototherapy candidates also must be willing and able to operate a machine and have dedicated space in their dwelling for it (most units are about the size of a door). Patients also have to be reliable, follow directions, and come back in person for follow-up appointments “so we can assess their response to treatment and fine-tune things as necessary and make sure they’re not developing any skin damage,” Dr. Gelfand said.

Educate yourself about existing options. Home phototherapy units from manufacturers such as Daavlin, National Biological Corporation, and SolRx range between $1200 and $6000 in cost, Dr. Gelfand said. He and his colleagues used the Daavlin 7 series in the LITE study. That unit features an integrated dosimetry system that delivers the correct dose of energy based on parameters that the prescribing clinician recommends. Settings are based on the patient’s skin type and how much the prescriber wants to increase the dose for each treatment. “The machine does the rest,” he said. “It knows what dose to give, so they get the same dosing as they would in an office situation.”

Smaller home-based phototherapy units designed to treat the hands and feet are available. So are handheld units to treat the scalp. “These can be a nice option for patients who have a few spots, but if the disease is moderate to severe, then it’s going to be pretty laborious to [use them],” Dr. Elmets said.

Remember that phototherapy is not a cure-all. According to the joint AAD-NPF guidelines, most phototherapy regimens require treatments two to three times per week for 10-14 weeks. Once patients achieve their home phototherapy treatment goal, Dr. Elmets often recommends treatments one to two times per week for maintenance.

“Patients with psoriasis have a lifetime condition,” he noted. “There are certainly cases where people have gone on phototherapy, cleared, and then stopped for a period of time. If they flare up, they can always go back to phototherapy. Usually, people who are on phototherapy use some type of topical agents to touch up areas that are resistant.”

Expect pushback from insurers on coverage. While Medicare and some integrated health plans cover home phototherapy, expect to spend time writing letters or placing phone calls to insurance companies to convince them why they should cover home phototherapy for candidate psoriasis patients. “Usually there’s a lot of letter writing and a long delay in getting approval,” Dr. Elmets said.

Dr. Elmets and Dr. Gelfand reported no relevant financial relationships. The LITE study was funded by the Patient-Centered Outcomes Research Institute. Research partners included the National Psoriasis Foundation and Daavlin, which provided the home phototherapy machines and covered the cost of shipping the devices.

A version of this article appeared on Medscape.com.

Supporters of home phototherapy for patients with plaque and guttate psoriasis had plenty to cheer about at the annual meeting of the American Academy of Dermatology (AAD) in March. There, Joel M. Gelfand, MD, professor of dermatology and epidemiology at the University of Pennsylvania in Philadelphia, presented results from the LITE study, a trial that tested the hypothesis that narrowband ultraviolet B phototherapy of psoriasis at home is noninferior to office treatment, based on outcomes that matter to patients, clinicians, and payers. While smaller studies have drawn similar conclusions, LITE was the largest trial of its kind to show what many dermatologists have suspected for years: Home phototherapy can be an effective first-line treatment for patients with moderate to severe psoriasis.

The co-primary outcomes in the LITE study were a Physician’s Global Assessment (PGA) score of 0/1 (clear, almost clear) and a Dermatology Life Quality Index (DLQI) score of 5 or less (small, no effect on health-related quality of life).

Dr. Gelfand and colleagues at 42 sites in the United States enrolled 783 patients aged 12 years and older who had plaque or guttate psoriasis and were candidates for phototherapy at home or in an office setting. Following 12 weeks of treatment, 25.6% of patients in the office-based phototherapy group achieved a PGA score of 0/1 compared with 32.8% of patients in the home-based phototherapy group (P > .0001 for noninferiority, non-response imputation for missing data). Similarly, 33.6% of patients in the office-based phototherapy group achieved a DLQI score of 5 or less compared with 52.4% of patients in the home-based phototherapy group (P > .0001 for noninferiority, non-response imputation for missing data).

Courtesy Dr. Gelfand

A Safe and Effective Option

“I think that it’s important for physicians, insurance companies, and patients with psoriasis to understand that this is a very safe and effective form of therapy,” Craig A. Elmets, MD, professor of dermatology at The University of Alabama at Birmingham, said in an interview. “For people who are not interested in systemic medications or who have contraindications to systemic medications, phototherapy would be ideal,” added Dr. Elmets, first author of the joint AAD–National Psoriasis Foundation (NPF) guidelines for the management and treatment of psoriasis with phototherapy, published in 2019.

Factors beyond efficacy support the role of home phototherapy, Dr. Gelfand said, including the fact that it costs 10-100 times less than biologics for psoriasis and that office-based phototherapy is not available in 90% of counties in the United States. However, insurance coverage of home phototherapy “is highly variable because until the LITE study, there was no large-scale US data to support its use,” he told this news organization.

“Also, insurance companies are broken up into two parts: Durable medical goods and the medical side such as pharmacy costs, and they are siloed. The durable medical goods side views phototherapy as expensive, while the pharmacy side views it as dirt cheap. This is part of the problem with our health system. A lot of things are siloed and don’t make any sense,” said Dr. Gelfand, director of the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania. By working with the NPF and payers, he added, “we’re hoping ... to transform the way insurance companies think about covering home phototherapy.”

In the meantime, he and Dr. Elmets shared practical ways to optimize access to home phototherapy for psoriasis patients:

Have the discussion. Patients “rarely bring this up as an option,” Dr. Elmets said, so the onus is on clinicians to talk about it. In his view, the ideal candidate “is averse to using systemic agents but whose disease is beyond the point where topical medicines alone will work. One of the advantages of phototherapy is that it doesn’t have immunosuppressive effects.”

Clinicians and patients can learn about the efficacy and safety of phototherapy for psoriasis, including home-based options, on the NPF’s web site and by reading the 2019 joint AAD-NPF guidelines.

Shared decision-making is key. “When a patient comes in, I’ll discuss what their treatment options are and [we] will decide upon a course of action based on their unique needs and preferences [and] if it’s medically appropriate, meaning they have the type of psoriasis likely to respond to phototherapy,” Dr. Gelfand said. A patient with psoriasis mainly on the fingernails or genitals “is not a good candidate for phototherapy. If it’s on the trunk or extremities, that patient would be a good candidate.”

Home phototherapy candidates also must be willing and able to operate a machine and have dedicated space in their dwelling for it (most units are about the size of a door). Patients also have to be reliable, follow directions, and come back in person for follow-up appointments “so we can assess their response to treatment and fine-tune things as necessary and make sure they’re not developing any skin damage,” Dr. Gelfand said.

Educate yourself about existing options. Home phototherapy units from manufacturers such as Daavlin, National Biological Corporation, and SolRx range between $1200 and $6000 in cost, Dr. Gelfand said. He and his colleagues used the Daavlin 7 series in the LITE study. That unit features an integrated dosimetry system that delivers the correct dose of energy based on parameters that the prescribing clinician recommends. Settings are based on the patient’s skin type and how much the prescriber wants to increase the dose for each treatment. “The machine does the rest,” he said. “It knows what dose to give, so they get the same dosing as they would in an office situation.”

Smaller home-based phototherapy units designed to treat the hands and feet are available. So are handheld units to treat the scalp. “These can be a nice option for patients who have a few spots, but if the disease is moderate to severe, then it’s going to be pretty laborious to [use them],” Dr. Elmets said.

Remember that phototherapy is not a cure-all. According to the joint AAD-NPF guidelines, most phototherapy regimens require treatments two to three times per week for 10-14 weeks. Once patients achieve their home phototherapy treatment goal, Dr. Elmets often recommends treatments one to two times per week for maintenance.

“Patients with psoriasis have a lifetime condition,” he noted. “There are certainly cases where people have gone on phototherapy, cleared, and then stopped for a period of time. If they flare up, they can always go back to phototherapy. Usually, people who are on phototherapy use some type of topical agents to touch up areas that are resistant.”

Expect pushback from insurers on coverage. While Medicare and some integrated health plans cover home phototherapy, expect to spend time writing letters or placing phone calls to insurance companies to convince them why they should cover home phototherapy for candidate psoriasis patients. “Usually there’s a lot of letter writing and a long delay in getting approval,” Dr. Elmets said.

Dr. Elmets and Dr. Gelfand reported no relevant financial relationships. The LITE study was funded by the Patient-Centered Outcomes Research Institute. Research partners included the National Psoriasis Foundation and Daavlin, which provided the home phototherapy machines and covered the cost of shipping the devices.

A version of this article appeared on Medscape.com.

Editor’s note: This article is adapted from an explanatory statement that Dr. Feldman wrote for the Coalition of State Rheumatology Organizations (CSRO).

According to the Guinness Book of World records, the longest time someone has held their breath underwater voluntarily is 24 minutes and 37.36 seconds. While certainly an amazing feat, UnitedHealthcare, many of the Blues, and other national “payers” are expecting rheumatologists and other specialists to live “underwater” in order to take care of their patients. In other words, these insurance companies are mandating that specialists use certain provider-administered biosimilars whose acquisition cost is higher than what the insurance company is willing to reimburse them. Essentially, the insurance companies expect the rheumatologists to pay them to take care of their patients. Because of the substantial and destabilizing financial losses incurred, many practices and free-standing infusion centers have been forced to cease offering these biosimilars. Most rheumatologists will provide patients with appropriate alternatives when available and permitted by the insurer; otherwise, they must refer patients to hospital-based infusion centers. That results in delayed care and increased costs for patients and the system, because hospital-based infusion typically costs more than twice what office-based infusion costs.

Quantifying the Problem

To help quantify the magnitude of this issue, the Coalition of State Rheumatology Organizations (CSRO) recently conducted a survey of its membership. A shocking 97% of respondents reported that their practice had been affected by reimbursement rates for some biosimilars being lower than acquisition costs, with 91% of respondents stating that this issue is more pronounced for certain biosimilars than others. Across the board, respondents most frequently identified Inflectra (infliximab-dyyb) and Avsola (infliximab-axxq) as being especially affected: Over 88% and over 85% of respondents identified these two products, respectively, as being underwater. These results support the ongoing anecdotal reports CSRO continues to receive from rheumatology practices.

However, the survey results indicated that this issue is by no means confined to those two biosimilars. Truxima (rituximab-abbs) — a biosimilar for Rituxan — was frequently mentioned as well. Notably, respondents almost uniformly identified biosimilars in the infliximab and rituximab families, which illustrates that this issue is no longer confined to one or two early-to-market biosimilars but has almost become a hallmark of this particular biosimilars market. Remarkably, one respondent commented that the brand products are now cheaper to acquire than the biosimilars. Furthermore, the survey included respondents from across the country, indicating that this issue is not confined to a particular region.
 

How Did This Happen?

Biosimilars held promise for increasing availability and decreasing biologic costs for patients but, thus far, no patients have seen their cost go down. It appears that the only biosimilars that have made it to “preferred” status on the formulary are the ones that have made more money for the middlemen in the drug supply chain, particularly those that construct formularies. Now, we have provider-administered biosimilars whose acquisition cost exceeds the reimbursement for these drugs. This disparity was ultimately created by biosimilar manufacturers “over-rebating” their drugs to health insurance companies to gain “fail-first” status on the formulary.

For example, the manufacturer of Inflectra offered substantial rebates to health insurers for preferred formulary placement. These rebates are factored into the sales price of the medication, which then results in a rapidly declining average sales price (ASP) for the biosimilar. Unfortunately, the acquisition cost for the drug does not experience commensurate reductions, resulting in physicians being reimbursed far less for the drug than it costs to acquire. The financial losses for physicians put them underwater as a result of the acquisition costs for the preferred drugs far surpassing the reimbursement from the health insurance company that constructed the formulary.

While various factors affect ASPs and acquisition costs, this particular consequence of formulary placement based on price concessions is a major driver of the underwater situation in which physicians have found themselves with many biosimilars. Not only does that lead to a lower uptake of biosimilars, but it also results in patients being referred to the hospital outpatient infusion sites to receive this care, as freestanding infusion centers cannot treat these patients either. Hospitals incur higher costs because of facility fees and elevated rates, and this makes private rheumatology in-office infusion centers a much lower-cost option. Similarly, home infusion services, while convenient, are marginally more expensive than private practices and, in cases of biologic infusions, it is important to note that physicians’ offices have a greater safety profile than home infusion of biologics. The overall result of these “fail-first underwater drugs” is delayed and more costly care for the patient and the “system,” particularly self-insured employers.
 

What Is Being Done to Correct This?

Since ASPs are updated quarterly, it is possible that acquisition costs and reimbursements might stabilize over time, making the drugs affordable again to practices. However, that does not appear to be happening in the near future, so that possibility does not offer immediate relief to struggling practices. It doesn’t promise a favorable outlook for future biosimilar entries of provider-administered medications if formularies continue to prefer the highest-rebated medication.

This dynamic between ASP and acquisition cost does not happen on the pharmacy side because the price concessions on specific drug rebates and fees are proprietary. There appears to be no equivalent to a publicly known ASP on the pharmacy side, which has led to myriad pricing definitions and manipulation on the pharmacy benefit side of medications. In any event, the savings from rebates and other manufacturer price concessions on pharmacy drugs do not influence ASPs of medical benefit drugs.

The Inflation Reduction Act provided a temporary increase in the add-on payment for biosimilars from ASP+6% to ASP+8%, but as long as the biosimilar’s ASP is lower than the reference brand’s ASP, that temporary increase does not appear to make up for the large differential between ASP and acquisition cost. It should be noted that any federal attempt to artificially lower the ASP of a provider-administered drug without a pathway assuring that the acquisition cost for the provider is less than the reimbursement is going to result in loss of access for patients to those medications and/or higher hospital site of care costs.
 

A Few Partial Fixes, But Most Complaints Go Ignored

Considering the higher costs of hospital-based infusion, insurers should be motivated to keep patients within private practices. Perhaps through insurers’ recognition of that fact, some practices have successfully negotiated exceptions for specific patients by discussing this situation with insurers. From the feedback that CSRO has received from rheumatology practices, it appears that most insurers have been ignoring the complaints from physicians. The few who have responded have resulted in only partial fixes, with some of the biosimilars still left underwater.

Ultimate Solution?

This issue is a direct result of the “rebate game,” whereby price concessions from drug manufacturers drive formulary placement. For provider-administered medications, this results in an artificially lowered ASP, not as a consequence of free-market incentives that benefit the patient, but as a result of misaligned incentives created by Safe Harbor–protected “kickbacks,” distorting the free market and paradoxically reducing access to these medications, delaying care, and increasing prices for patients and the healthcare system.

While federal and state governments are not likely to address this particular situation in the biosimilars market, CSRO is highlighting this issue as a prime example of why the current formulary construction system urgently requires federal reform. At this time, the biosimilars most affected are Inflectra and Avsola, but if nothing changes, more and more biosimilars will fall victim to the short-sighted pricing strategy of aggressive rebating to gain formulary position, with physician purchasers and patients left to navigate the aftermath. The existing system, which necessitates drug companies purchasing formulary access from pharmacy benefit managers, has led to delayed and even denied patient access to certain provider-administered drugs. Moreover, it now appears to be hindering the adoption of biosimilars.

To address this, a multifaceted approach is required. It not only involves reevaluating the rebate system and its impact on formulary construction and ASP, but also ensuring that acquisition costs for providers are aligned with reimbursement rates. Insurers must recognize the economic and clinical value of maintaining infusions within private practices and immediately update their policies to ensure that physician in-office infusion is financially feasible for these “fail-first” biosimilars.

Ultimately, the goal should be to create a sustainable model that promotes the use of affordable biosimilars, enhances patient access to affordable care, and supports the financial viability of medical practices. Concerted efforts to reform the current formulary construction system are required to achieve a healthcare environment that is both cost effective and patient centric.

Dr. Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans. She is the CSRO’s vice president of advocacy and government affairs and its immediate past president, as well as past chair of the Alliance for Safe Biologic Medicines and a past member of the American College of Rheumatology insurance subcommittee. You can reach her at [email protected].

Editor’s note: This article is adapted from an explanatory statement that Dr. Feldman wrote for the Coalition of State Rheumatology Organizations (CSRO).

According to the Guinness Book of World records, the longest time someone has held their breath underwater voluntarily is 24 minutes and 37.36 seconds. While certainly an amazing feat, UnitedHealthcare, many of the Blues, and other national “payers” are expecting rheumatologists and other specialists to live “underwater” in order to take care of their patients. In other words, these insurance companies are mandating that specialists use certain provider-administered biosimilars whose acquisition cost is higher than what the insurance company is willing to reimburse them. Essentially, the insurance companies expect the rheumatologists to pay them to take care of their patients. Because of the substantial and destabilizing financial losses incurred, many practices and free-standing infusion centers have been forced to cease offering these biosimilars. Most rheumatologists will provide patients with appropriate alternatives when available and permitted by the insurer; otherwise, they must refer patients to hospital-based infusion centers. That results in delayed care and increased costs for patients and the system, because hospital-based infusion typically costs more than twice what office-based infusion costs.

Quantifying the Problem

To help quantify the magnitude of this issue, the Coalition of State Rheumatology Organizations (CSRO) recently conducted a survey of its membership. A shocking 97% of respondents reported that their practice had been affected by reimbursement rates for some biosimilars being lower than acquisition costs, with 91% of respondents stating that this issue is more pronounced for certain biosimilars than others. Across the board, respondents most frequently identified Inflectra (infliximab-dyyb) and Avsola (infliximab-axxq) as being especially affected: Over 88% and over 85% of respondents identified these two products, respectively, as being underwater. These results support the ongoing anecdotal reports CSRO continues to receive from rheumatology practices.

However, the survey results indicated that this issue is by no means confined to those two biosimilars. Truxima (rituximab-abbs) — a biosimilar for Rituxan — was frequently mentioned as well. Notably, respondents almost uniformly identified biosimilars in the infliximab and rituximab families, which illustrates that this issue is no longer confined to one or two early-to-market biosimilars but has almost become a hallmark of this particular biosimilars market. Remarkably, one respondent commented that the brand products are now cheaper to acquire than the biosimilars. Furthermore, the survey included respondents from across the country, indicating that this issue is not confined to a particular region.
 

How Did This Happen?

Biosimilars held promise for increasing availability and decreasing biologic costs for patients but, thus far, no patients have seen their cost go down. It appears that the only biosimilars that have made it to “preferred” status on the formulary are the ones that have made more money for the middlemen in the drug supply chain, particularly those that construct formularies. Now, we have provider-administered biosimilars whose acquisition cost exceeds the reimbursement for these drugs. This disparity was ultimately created by biosimilar manufacturers “over-rebating” their drugs to health insurance companies to gain “fail-first” status on the formulary.

For example, the manufacturer of Inflectra offered substantial rebates to health insurers for preferred formulary placement. These rebates are factored into the sales price of the medication, which then results in a rapidly declining average sales price (ASP) for the biosimilar. Unfortunately, the acquisition cost for the drug does not experience commensurate reductions, resulting in physicians being reimbursed far less for the drug than it costs to acquire. The financial losses for physicians put them underwater as a result of the acquisition costs for the preferred drugs far surpassing the reimbursement from the health insurance company that constructed the formulary.

While various factors affect ASPs and acquisition costs, this particular consequence of formulary placement based on price concessions is a major driver of the underwater situation in which physicians have found themselves with many biosimilars. Not only does that lead to a lower uptake of biosimilars, but it also results in patients being referred to the hospital outpatient infusion sites to receive this care, as freestanding infusion centers cannot treat these patients either. Hospitals incur higher costs because of facility fees and elevated rates, and this makes private rheumatology in-office infusion centers a much lower-cost option. Similarly, home infusion services, while convenient, are marginally more expensive than private practices and, in cases of biologic infusions, it is important to note that physicians’ offices have a greater safety profile than home infusion of biologics. The overall result of these “fail-first underwater drugs” is delayed and more costly care for the patient and the “system,” particularly self-insured employers.
 

What Is Being Done to Correct This?

Since ASPs are updated quarterly, it is possible that acquisition costs and reimbursements might stabilize over time, making the drugs affordable again to practices. However, that does not appear to be happening in the near future, so that possibility does not offer immediate relief to struggling practices. It doesn’t promise a favorable outlook for future biosimilar entries of provider-administered medications if formularies continue to prefer the highest-rebated medication.

This dynamic between ASP and acquisition cost does not happen on the pharmacy side because the price concessions on specific drug rebates and fees are proprietary. There appears to be no equivalent to a publicly known ASP on the pharmacy side, which has led to myriad pricing definitions and manipulation on the pharmacy benefit side of medications. In any event, the savings from rebates and other manufacturer price concessions on pharmacy drugs do not influence ASPs of medical benefit drugs.

The Inflation Reduction Act provided a temporary increase in the add-on payment for biosimilars from ASP+6% to ASP+8%, but as long as the biosimilar’s ASP is lower than the reference brand’s ASP, that temporary increase does not appear to make up for the large differential between ASP and acquisition cost. It should be noted that any federal attempt to artificially lower the ASP of a provider-administered drug without a pathway assuring that the acquisition cost for the provider is less than the reimbursement is going to result in loss of access for patients to those medications and/or higher hospital site of care costs.
 

A Few Partial Fixes, But Most Complaints Go Ignored

Considering the higher costs of hospital-based infusion, insurers should be motivated to keep patients within private practices. Perhaps through insurers’ recognition of that fact, some practices have successfully negotiated exceptions for specific patients by discussing this situation with insurers. From the feedback that CSRO has received from rheumatology practices, it appears that most insurers have been ignoring the complaints from physicians. The few who have responded have resulted in only partial fixes, with some of the biosimilars still left underwater.

Ultimate Solution?

This issue is a direct result of the “rebate game,” whereby price concessions from drug manufacturers drive formulary placement. For provider-administered medications, this results in an artificially lowered ASP, not as a consequence of free-market incentives that benefit the patient, but as a result of misaligned incentives created by Safe Harbor–protected “kickbacks,” distorting the free market and paradoxically reducing access to these medications, delaying care, and increasing prices for patients and the healthcare system.

While federal and state governments are not likely to address this particular situation in the biosimilars market, CSRO is highlighting this issue as a prime example of why the current formulary construction system urgently requires federal reform. At this time, the biosimilars most affected are Inflectra and Avsola, but if nothing changes, more and more biosimilars will fall victim to the short-sighted pricing strategy of aggressive rebating to gain formulary position, with physician purchasers and patients left to navigate the aftermath. The existing system, which necessitates drug companies purchasing formulary access from pharmacy benefit managers, has led to delayed and even denied patient access to certain provider-administered drugs. Moreover, it now appears to be hindering the adoption of biosimilars.

To address this, a multifaceted approach is required. It not only involves reevaluating the rebate system and its impact on formulary construction and ASP, but also ensuring that acquisition costs for providers are aligned with reimbursement rates. Insurers must recognize the economic and clinical value of maintaining infusions within private practices and immediately update their policies to ensure that physician in-office infusion is financially feasible for these “fail-first” biosimilars.

Ultimately, the goal should be to create a sustainable model that promotes the use of affordable biosimilars, enhances patient access to affordable care, and supports the financial viability of medical practices. Concerted efforts to reform the current formulary construction system are required to achieve a healthcare environment that is both cost effective and patient centric.

Dr. Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans. She is the CSRO’s vice president of advocacy and government affairs and its immediate past president, as well as past chair of the Alliance for Safe Biologic Medicines and a past member of the American College of Rheumatology insurance subcommittee. You can reach her at [email protected].

Editor’s note: This article is adapted from an explanatory statement that Dr. Feldman wrote for the Coalition of State Rheumatology Organizations (CSRO).

According to the Guinness Book of World records, the longest time someone has held their breath underwater voluntarily is 24 minutes and 37.36 seconds. While certainly an amazing feat, UnitedHealthcare, many of the Blues, and other national “payers” are expecting rheumatologists and other specialists to live “underwater” in order to take care of their patients. In other words, these insurance companies are mandating that specialists use certain provider-administered biosimilars whose acquisition cost is higher than what the insurance company is willing to reimburse them. Essentially, the insurance companies expect the rheumatologists to pay them to take care of their patients. Because of the substantial and destabilizing financial losses incurred, many practices and free-standing infusion centers have been forced to cease offering these biosimilars. Most rheumatologists will provide patients with appropriate alternatives when available and permitted by the insurer; otherwise, they must refer patients to hospital-based infusion centers. That results in delayed care and increased costs for patients and the system, because hospital-based infusion typically costs more than twice what office-based infusion costs.

Quantifying the Problem

To help quantify the magnitude of this issue, the Coalition of State Rheumatology Organizations (CSRO) recently conducted a survey of its membership. A shocking 97% of respondents reported that their practice had been affected by reimbursement rates for some biosimilars being lower than acquisition costs, with 91% of respondents stating that this issue is more pronounced for certain biosimilars than others. Across the board, respondents most frequently identified Inflectra (infliximab-dyyb) and Avsola (infliximab-axxq) as being especially affected: Over 88% and over 85% of respondents identified these two products, respectively, as being underwater. These results support the ongoing anecdotal reports CSRO continues to receive from rheumatology practices.

However, the survey results indicated that this issue is by no means confined to those two biosimilars. Truxima (rituximab-abbs) — a biosimilar for Rituxan — was frequently mentioned as well. Notably, respondents almost uniformly identified biosimilars in the infliximab and rituximab families, which illustrates that this issue is no longer confined to one or two early-to-market biosimilars but has almost become a hallmark of this particular biosimilars market. Remarkably, one respondent commented that the brand products are now cheaper to acquire than the biosimilars. Furthermore, the survey included respondents from across the country, indicating that this issue is not confined to a particular region.
 

How Did This Happen?

Biosimilars held promise for increasing availability and decreasing biologic costs for patients but, thus far, no patients have seen their cost go down. It appears that the only biosimilars that have made it to “preferred” status on the formulary are the ones that have made more money for the middlemen in the drug supply chain, particularly those that construct formularies. Now, we have provider-administered biosimilars whose acquisition cost exceeds the reimbursement for these drugs. This disparity was ultimately created by biosimilar manufacturers “over-rebating” their drugs to health insurance companies to gain “fail-first” status on the formulary.

For example, the manufacturer of Inflectra offered substantial rebates to health insurers for preferred formulary placement. These rebates are factored into the sales price of the medication, which then results in a rapidly declining average sales price (ASP) for the biosimilar. Unfortunately, the acquisition cost for the drug does not experience commensurate reductions, resulting in physicians being reimbursed far less for the drug than it costs to acquire. The financial losses for physicians put them underwater as a result of the acquisition costs for the preferred drugs far surpassing the reimbursement from the health insurance company that constructed the formulary.

While various factors affect ASPs and acquisition costs, this particular consequence of formulary placement based on price concessions is a major driver of the underwater situation in which physicians have found themselves with many biosimilars. Not only does that lead to a lower uptake of biosimilars, but it also results in patients being referred to the hospital outpatient infusion sites to receive this care, as freestanding infusion centers cannot treat these patients either. Hospitals incur higher costs because of facility fees and elevated rates, and this makes private rheumatology in-office infusion centers a much lower-cost option. Similarly, home infusion services, while convenient, are marginally more expensive than private practices and, in cases of biologic infusions, it is important to note that physicians’ offices have a greater safety profile than home infusion of biologics. The overall result of these “fail-first underwater drugs” is delayed and more costly care for the patient and the “system,” particularly self-insured employers.
 

What Is Being Done to Correct This?

Since ASPs are updated quarterly, it is possible that acquisition costs and reimbursements might stabilize over time, making the drugs affordable again to practices. However, that does not appear to be happening in the near future, so that possibility does not offer immediate relief to struggling practices. It doesn’t promise a favorable outlook for future biosimilar entries of provider-administered medications if formularies continue to prefer the highest-rebated medication.

This dynamic between ASP and acquisition cost does not happen on the pharmacy side because the price concessions on specific drug rebates and fees are proprietary. There appears to be no equivalent to a publicly known ASP on the pharmacy side, which has led to myriad pricing definitions and manipulation on the pharmacy benefit side of medications. In any event, the savings from rebates and other manufacturer price concessions on pharmacy drugs do not influence ASPs of medical benefit drugs.

The Inflation Reduction Act provided a temporary increase in the add-on payment for biosimilars from ASP+6% to ASP+8%, but as long as the biosimilar’s ASP is lower than the reference brand’s ASP, that temporary increase does not appear to make up for the large differential between ASP and acquisition cost. It should be noted that any federal attempt to artificially lower the ASP of a provider-administered drug without a pathway assuring that the acquisition cost for the provider is less than the reimbursement is going to result in loss of access for patients to those medications and/or higher hospital site of care costs.
 

A Few Partial Fixes, But Most Complaints Go Ignored

Considering the higher costs of hospital-based infusion, insurers should be motivated to keep patients within private practices. Perhaps through insurers’ recognition of that fact, some practices have successfully negotiated exceptions for specific patients by discussing this situation with insurers. From the feedback that CSRO has received from rheumatology practices, it appears that most insurers have been ignoring the complaints from physicians. The few who have responded have resulted in only partial fixes, with some of the biosimilars still left underwater.

Ultimate Solution?

This issue is a direct result of the “rebate game,” whereby price concessions from drug manufacturers drive formulary placement. For provider-administered medications, this results in an artificially lowered ASP, not as a consequence of free-market incentives that benefit the patient, but as a result of misaligned incentives created by Safe Harbor–protected “kickbacks,” distorting the free market and paradoxically reducing access to these medications, delaying care, and increasing prices for patients and the healthcare system.

While federal and state governments are not likely to address this particular situation in the biosimilars market, CSRO is highlighting this issue as a prime example of why the current formulary construction system urgently requires federal reform. At this time, the biosimilars most affected are Inflectra and Avsola, but if nothing changes, more and more biosimilars will fall victim to the short-sighted pricing strategy of aggressive rebating to gain formulary position, with physician purchasers and patients left to navigate the aftermath. The existing system, which necessitates drug companies purchasing formulary access from pharmacy benefit managers, has led to delayed and even denied patient access to certain provider-administered drugs. Moreover, it now appears to be hindering the adoption of biosimilars.

To address this, a multifaceted approach is required. It not only involves reevaluating the rebate system and its impact on formulary construction and ASP, but also ensuring that acquisition costs for providers are aligned with reimbursement rates. Insurers must recognize the economic and clinical value of maintaining infusions within private practices and immediately update their policies to ensure that physician in-office infusion is financially feasible for these “fail-first” biosimilars.

Ultimately, the goal should be to create a sustainable model that promotes the use of affordable biosimilars, enhances patient access to affordable care, and supports the financial viability of medical practices. Concerted efforts to reform the current formulary construction system are required to achieve a healthcare environment that is both cost effective and patient centric.

Dr. Feldman is a rheumatologist in private practice with The Rheumatology Group in New Orleans. She is the CSRO’s vice president of advocacy and government affairs and its immediate past president, as well as past chair of the Alliance for Safe Biologic Medicines and a past member of the American College of Rheumatology insurance subcommittee. You can reach her at [email protected].

Key clinical point: Red cell distribution width (RDW) and mean platelet volume (MPV) can be used to detect enthesitis in patients with psoriatic arthritis (psoriatic enthesopathy) with musculoskeletal ultrasound scores.

Major finding: There was a significant association between clinical tenderness, presence of enthesophytes on plain radiography, and musculoskeletal ultrasound findings at entheses sites (P < .001 for each). RDW (P = .010) and MPV (P = .001) levels were elevated in patients with psoriatic enthesopathy vs control individuals without the disease, with the hematological indices being positively correlated with disease activity scores (P < .001).

Study details: This case-control study included 30 patients with psoriatic enthesopathy and 20 control individuals without the disease (age > 18 years).

Disclosures: This study received open access funding from The Science, Technology & Innovation Funding Authority in cooperation with The Egyptian Knowledge Bank. The authors declared no conflict of interests.

Source: Amer AS, Al Shambaky AY, Ameen SG, Sobih AK. Hematological indices in psoriatic enthesopathy: Relation to clinical and ultrasound evaluation. Clin Rheumatol. Published online April 8, 2024. Source

Key clinical point: Red cell distribution width (RDW) and mean platelet volume (MPV) can be used to detect enthesitis in patients with psoriatic arthritis (psoriatic enthesopathy) with musculoskeletal ultrasound scores.

Major finding: There was a significant association between clinical tenderness, presence of enthesophytes on plain radiography, and musculoskeletal ultrasound findings at entheses sites (P < .001 for each). RDW (P = .010) and MPV (P = .001) levels were elevated in patients with psoriatic enthesopathy vs control individuals without the disease, with the hematological indices being positively correlated with disease activity scores (P < .001).

Study details: This case-control study included 30 patients with psoriatic enthesopathy and 20 control individuals without the disease (age > 18 years).

Disclosures: This study received open access funding from The Science, Technology & Innovation Funding Authority in cooperation with The Egyptian Knowledge Bank. The authors declared no conflict of interests.

Source: Amer AS, Al Shambaky AY, Ameen SG, Sobih AK. Hematological indices in psoriatic enthesopathy: Relation to clinical and ultrasound evaluation. Clin Rheumatol. Published online April 8, 2024. Source

Key clinical point: Red cell distribution width (RDW) and mean platelet volume (MPV) can be used to detect enthesitis in patients with psoriatic arthritis (psoriatic enthesopathy) with musculoskeletal ultrasound scores.

Major finding: There was a significant association between clinical tenderness, presence of enthesophytes on plain radiography, and musculoskeletal ultrasound findings at entheses sites (P < .001 for each). RDW (P = .010) and MPV (P = .001) levels were elevated in patients with psoriatic enthesopathy vs control individuals without the disease, with the hematological indices being positively correlated with disease activity scores (P < .001).

Study details: This case-control study included 30 patients with psoriatic enthesopathy and 20 control individuals without the disease (age > 18 years).

Disclosures: This study received open access funding from The Science, Technology & Innovation Funding Authority in cooperation with The Egyptian Knowledge Bank. The authors declared no conflict of interests.

Source: Amer AS, Al Shambaky AY, Ameen SG, Sobih AK. Hematological indices in psoriatic enthesopathy: Relation to clinical and ultrasound evaluation. Clin Rheumatol. Published online April 8, 2024. Source

Key clinical point: Ultrasound assessment showed reduced thickness of nail bed and adjacent skin in clinically healthy nails of patients with psoriatic arthritis (PsA) than in control individuals without the disease.

Major finding: Ultrasound identified more morphological changes in the clinically healthy nails of patients with PsA vs control individuals (16.89% vs 3.33%; P = .03), along with significantly lower thickness of nail bed (1.77 mm vs 2.07 mm; P = .027) and adjacent skin (2.26 mm vs 2.59 mm; P = .003). Also, the adjacent skin thickness was positively correlated with tender joint count (correlation coefficient, 0.46; P = .03), suggesting that it can be used as a disease activity indicator.

Study details: This cross-sectional study involved the ultrasound assessment of clinically healthy nails in 22 patients with PsA (219 nails) who were compared with 21 control individuals without PsA (210 nails).

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Mahmoud I, Rouached L, Rahmouni S, et al. Ultrasound assessment of psoriatic arthritis patients with clinically normal nails and evaluation of its correlation with the disease activity: A case-control study. J Ultrasound Med. Published online April 18, 2024. Source

Key clinical point: Ultrasound assessment showed reduced thickness of nail bed and adjacent skin in clinically healthy nails of patients with psoriatic arthritis (PsA) than in control individuals without the disease.

Major finding: Ultrasound identified more morphological changes in the clinically healthy nails of patients with PsA vs control individuals (16.89% vs 3.33%; P = .03), along with significantly lower thickness of nail bed (1.77 mm vs 2.07 mm; P = .027) and adjacent skin (2.26 mm vs 2.59 mm; P = .003). Also, the adjacent skin thickness was positively correlated with tender joint count (correlation coefficient, 0.46; P = .03), suggesting that it can be used as a disease activity indicator.

Study details: This cross-sectional study involved the ultrasound assessment of clinically healthy nails in 22 patients with PsA (219 nails) who were compared with 21 control individuals without PsA (210 nails).

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Mahmoud I, Rouached L, Rahmouni S, et al. Ultrasound assessment of psoriatic arthritis patients with clinically normal nails and evaluation of its correlation with the disease activity: A case-control study. J Ultrasound Med. Published online April 18, 2024. Source

Key clinical point: Ultrasound assessment showed reduced thickness of nail bed and adjacent skin in clinically healthy nails of patients with psoriatic arthritis (PsA) than in control individuals without the disease.

Major finding: Ultrasound identified more morphological changes in the clinically healthy nails of patients with PsA vs control individuals (16.89% vs 3.33%; P = .03), along with significantly lower thickness of nail bed (1.77 mm vs 2.07 mm; P = .027) and adjacent skin (2.26 mm vs 2.59 mm; P = .003). Also, the adjacent skin thickness was positively correlated with tender joint count (correlation coefficient, 0.46; P = .03), suggesting that it can be used as a disease activity indicator.

Study details: This cross-sectional study involved the ultrasound assessment of clinically healthy nails in 22 patients with PsA (219 nails) who were compared with 21 control individuals without PsA (210 nails).

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Mahmoud I, Rouached L, Rahmouni S, et al. Ultrasound assessment of psoriatic arthritis patients with clinically normal nails and evaluation of its correlation with the disease activity: A case-control study. J Ultrasound Med. Published online April 18, 2024. Source

Key clinical point: Bimekizumab demonstrated superior efficacy than placebo and had an acceptable safety profile in patients with psoriatic arthritis (PsA).

Major finding: Bimekizumab vs placebo led to a significantly higher response rate for minimal disease activity (risk ratio [RR], 4.188; P < .001), ≥ 70% improvement in the American College of Rheumatology criteria (RR, 7.932; P < .0001). Bimekizumab was superior to placebo in achieving ACR20/50/70 response at a dose of 160 mg. The risk for treatment-emergent adverse events was modestly higher with bimekizumab vs placebo (RR, 1.423; P = .023), whereas that for serious malignancies, upper respiratory tract infection, injection site reactions, and pharyngitis was similar for both.

Study details: This meta-analysis of four placebo-controlled randomized clinical trials included 1323 patients with PsA (age, ≥ 18 years), of whom 853 received bimekizumab.

Disclosures: This study was supported by the National Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflict of interests.

Source: Su QY, Yang L, Cao TY, et al. Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis. Expert Opin Drug Saf. Published online April 23, 2024. Source

Key clinical point: Bimekizumab demonstrated superior efficacy than placebo and had an acceptable safety profile in patients with psoriatic arthritis (PsA).

Major finding: Bimekizumab vs placebo led to a significantly higher response rate for minimal disease activity (risk ratio [RR], 4.188; P < .001), ≥ 70% improvement in the American College of Rheumatology criteria (RR, 7.932; P < .0001). Bimekizumab was superior to placebo in achieving ACR20/50/70 response at a dose of 160 mg. The risk for treatment-emergent adverse events was modestly higher with bimekizumab vs placebo (RR, 1.423; P = .023), whereas that for serious malignancies, upper respiratory tract infection, injection site reactions, and pharyngitis was similar for both.

Study details: This meta-analysis of four placebo-controlled randomized clinical trials included 1323 patients with PsA (age, ≥ 18 years), of whom 853 received bimekizumab.

Disclosures: This study was supported by the National Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflict of interests.

Source: Su QY, Yang L, Cao TY, et al. Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis. Expert Opin Drug Saf. Published online April 23, 2024. Source

Key clinical point: Bimekizumab demonstrated superior efficacy than placebo and had an acceptable safety profile in patients with psoriatic arthritis (PsA).

Major finding: Bimekizumab vs placebo led to a significantly higher response rate for minimal disease activity (risk ratio [RR], 4.188; P < .001), ≥ 70% improvement in the American College of Rheumatology criteria (RR, 7.932; P < .0001). Bimekizumab was superior to placebo in achieving ACR20/50/70 response at a dose of 160 mg. The risk for treatment-emergent adverse events was modestly higher with bimekizumab vs placebo (RR, 1.423; P = .023), whereas that for serious malignancies, upper respiratory tract infection, injection site reactions, and pharyngitis was similar for both.

Study details: This meta-analysis of four placebo-controlled randomized clinical trials included 1323 patients with PsA (age, ≥ 18 years), of whom 853 received bimekizumab.

Disclosures: This study was supported by the National Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflict of interests.

Source: Su QY, Yang L, Cao TY, et al. Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis. Expert Opin Drug Saf. Published online April 23, 2024. Source

Key clinical point: Eta (14-3-3η) protein could serve as a potential biomarker in the differential diagnosis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) because patients with PsA showed significantly lower serum levels of eta protein than patients with RA.

Major finding: Eta protein levels were significantly lower in patients with PsA vs RA (regression coefficient [B], −0.341, odds ratio [OR], 0.711; P = .007). A cutoff value of 2.64 ng/mL for eta protein could distinguish between PsA and RA with 54.7% sensitivity and 77.8% specificity (area under the curve, 0.686; P = .001).

Study details: This case-control study included 54 patients with PsA, 53 with RA, and 56 healthy individuals without any rheumatological disease, whose eta protein levels were detected using enzyme-linked immunosorbent assay.

Disclosures: This study was funded by a grant from the Turkish Rheumatology Association. The authors declared no conflict of interests.

Source: Kor A, Orhan K, Maraş Y, et al. Does Eta protein differentiate rheumatoid arthritis from psoriatic arthritis? Curr Med Chem. Published online April 27, 2024. Source

Key clinical point: Eta (14-3-3η) protein could serve as a potential biomarker in the differential diagnosis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) because patients with PsA showed significantly lower serum levels of eta protein than patients with RA.

Major finding: Eta protein levels were significantly lower in patients with PsA vs RA (regression coefficient [B], −0.341, odds ratio [OR], 0.711; P = .007). A cutoff value of 2.64 ng/mL for eta protein could distinguish between PsA and RA with 54.7% sensitivity and 77.8% specificity (area under the curve, 0.686; P = .001).

Study details: This case-control study included 54 patients with PsA, 53 with RA, and 56 healthy individuals without any rheumatological disease, whose eta protein levels were detected using enzyme-linked immunosorbent assay.

Disclosures: This study was funded by a grant from the Turkish Rheumatology Association. The authors declared no conflict of interests.

Source: Kor A, Orhan K, Maraş Y, et al. Does Eta protein differentiate rheumatoid arthritis from psoriatic arthritis? Curr Med Chem. Published online April 27, 2024. Source

Key clinical point: Eta (14-3-3η) protein could serve as a potential biomarker in the differential diagnosis of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) because patients with PsA showed significantly lower serum levels of eta protein than patients with RA.

Major finding: Eta protein levels were significantly lower in patients with PsA vs RA (regression coefficient [B], −0.341, odds ratio [OR], 0.711; P = .007). A cutoff value of 2.64 ng/mL for eta protein could distinguish between PsA and RA with 54.7% sensitivity and 77.8% specificity (area under the curve, 0.686; P = .001).

Study details: This case-control study included 54 patients with PsA, 53 with RA, and 56 healthy individuals without any rheumatological disease, whose eta protein levels were detected using enzyme-linked immunosorbent assay.

Disclosures: This study was funded by a grant from the Turkish Rheumatology Association. The authors declared no conflict of interests.

Source: Kor A, Orhan K, Maraş Y, et al. Does Eta protein differentiate rheumatoid arthritis from psoriatic arthritis? Curr Med Chem. Published online April 27, 2024. Source

Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).

Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.

Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.

Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.

Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source

Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).

Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.

Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.

Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.

Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source

Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).

Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.

Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.

Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.

Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source

Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.

Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).

Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source

Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.

Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).

Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source

Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.

Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).

Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source

Key clinical point: Risk factors for psoriasis developing into clinical psoriatic arthritis (PsA) include higher age, nail involvement, increased erythrocyte sedimentation rate (ESR), and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Major finding: Age ≥ 40 years (odds ratio [OR], 1.04; P < .01), nail involvement (OR, 1.17; P < .01), increased ESR (OR, 1.03; P < .05), and elevated hs-CRP levels (OR, 1.31; P < .01) increased the risk for incident PsA in patients with psoriasis. Moreover, MRI-detected enthesitis and tenosynovitis combined with these risk factors vs the risk factors alone showed better specificity (94.3% vs 69.0%) and similar sensitivity (89.0% vs 84.6%) in diagnosing PsA.

Study details: This longitudinal case-control study included 75 patients diagnosed with clinical PsA who were compared with 345 patients with psoriasis and without PsA, all of whom were aged 18-65 years.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Project. The authors declared no conflict of interests.

Source: Yao A, Wang L, Qi F, et al. Risk factors and early detection of joint damage in patients with psoriasis: A case–control study. Int J Dermatol. Published online April 29, 2024. Source

Key clinical point: Risk factors for psoriasis developing into clinical psoriatic arthritis (PsA) include higher age, nail involvement, increased erythrocyte sedimentation rate (ESR), and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Major finding: Age ≥ 40 years (odds ratio [OR], 1.04; P < .01), nail involvement (OR, 1.17; P < .01), increased ESR (OR, 1.03; P < .05), and elevated hs-CRP levels (OR, 1.31; P < .01) increased the risk for incident PsA in patients with psoriasis. Moreover, MRI-detected enthesitis and tenosynovitis combined with these risk factors vs the risk factors alone showed better specificity (94.3% vs 69.0%) and similar sensitivity (89.0% vs 84.6%) in diagnosing PsA.

Study details: This longitudinal case-control study included 75 patients diagnosed with clinical PsA who were compared with 345 patients with psoriasis and without PsA, all of whom were aged 18-65 years.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Project. The authors declared no conflict of interests.

Source: Yao A, Wang L, Qi F, et al. Risk factors and early detection of joint damage in patients with psoriasis: A case–control study. Int J Dermatol. Published online April 29, 2024. Source

Key clinical point: Risk factors for psoriasis developing into clinical psoriatic arthritis (PsA) include higher age, nail involvement, increased erythrocyte sedimentation rate (ESR), and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Major finding: Age ≥ 40 years (odds ratio [OR], 1.04; P < .01), nail involvement (OR, 1.17; P < .01), increased ESR (OR, 1.03; P < .05), and elevated hs-CRP levels (OR, 1.31; P < .01) increased the risk for incident PsA in patients with psoriasis. Moreover, MRI-detected enthesitis and tenosynovitis combined with these risk factors vs the risk factors alone showed better specificity (94.3% vs 69.0%) and similar sensitivity (89.0% vs 84.6%) in diagnosing PsA.

Study details: This longitudinal case-control study included 75 patients diagnosed with clinical PsA who were compared with 345 patients with psoriasis and without PsA, all of whom were aged 18-65 years.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Project. The authors declared no conflict of interests.

Source: Yao A, Wang L, Qi F, et al. Risk factors and early detection of joint damage in patients with psoriasis: A case–control study. Int J Dermatol. Published online April 29, 2024. Source